US00850.1740B2 (12) United States Patent (10) Patent No.: US 8,501,740 B2 Gutstein (45) Date of Patent: Aug. 6, 2013 (54) METHODS OF TREATMENT OF OPIOID FOREIGN PATENT DOCUMENTS TOLERANCE, PHYSICAL DEPENDENCE, WO WO O2/O58687 A2 * 8, 2002 PAN AND ADDCTION WITH INHIBITORS OF CERTAIN GROWTH FACTOR OTHER PUBLICATIONS RECEPTORS Polakiewicz et al. 1998, “A Mitogen-activated protein kinase path (75) Inventor: Howard Gutstein, Bellaire, TX (US) way is required for u-opioid receptor desensitization.” Journal of Biological Chemistry, vol. 273, No. 20, pp. 12402-12406.* (73) Assignee: Board of Regents, The University of Elliott et al. 1994, "The NMDA receptor antagonists, LY274614 and Texas System, Austin, TX (US) MK-801, and the nitric oxide synthase inhibitor, NG-nitro-L- arginine ...” Pain, vol. 56, pp. 69-75.* (*) Notice: Subject to any disclaimer, the term of this Kolesnikov et al. 1993, “Blockade oftolerance to morphinebut not to patent is extended or adjusted under 35 k-opioids by a nitric oxide synthase inhibitor.” Proc. Natl. Acad. Sci., U.S.C. 154(b) by 120 days. vol. 90, pp. 5162-5166.* (21) Appl. No.: 12/682,064 Fierro et al. 2007. "Inhibition of platelet-derived growth factor receptorb by imatinib mesylate Suppresses proliferation and alters (22) PCT Filed: Oct. 8, 2008 differentiation of human mesenchymal stem cells in vitro.” Cell Prolif., vol. 40, pp. 355-366.* (86). PCT No.: PCT/US2008/079198 Paniagua et al. 2006, "Selective tyrosine inhibition by imatinib mesylate for the treatment of autoimmune arthritis.” The Journal of S371 (c)(1), Clinical Investigation, vol. 116, No. 10, pp. 2633-2642.* (2), (4) Date: Apr. 8, 2010 Brewster et al., May 29, 2007, “Cyclodextrins as pharmaceutical solubilizers.” Advanced Drug Delivery Reviews, vol. 59, pp. 645 (87) PCT Pub. No.: WO2009/048947 666. PCT Pub. Date: Apr. 16, 2009 Beni, Szabolcs, et al., Cyclodextrin/Imatinib Complexation: Binding mode and Charge Dependent Stabilities, Science DirectNov. 7, 2006. (65) Prior Publication Data leCoutre, Phillipp, et al., Pharmacokinetics and Cellular Uptake of US 2010/0210709 A1 Aug. 19, 2010 Imatinib and its Main Metabolite CGP74588, Cancer Chemother Pharmacol, Dec. 5, 2003. Peng, Bin, et al., Absolute Bioavailability of Imatinib (Glivec) Orally Related U.S. Application Data Versus Intravenous Infusion, Journal of Clinical Pharmacology 44:158-162(2004). (60) Provisional application No. 60/978,641, filed on Oct. Ahmed, S.H. and G. F. Koob, Transition from Moderate to Excessive 9, 2007. Drug Intake: Change in Hedonic Set Point. Science, 1998. (51) Int. Cl. 282((5387) Oct. 9): p. 298-300. A 6LX3L/2197 (2006.01) Ahmed, S.H., J.R. Walker, and G.F. Koob, Persistent Increase in the AOIN 43/54 (2006.01) Motivation to Take Heroin in Rats With a History of Drug Escalation. CO7D 239/42 (2006.01) Neuropsychopharmacology, 2000. 22: p. 413-421. Arteaga, C., et. al., A Phase I-II Study of Combined Blockade of the CO7D40 L/04 (2006.01) ErbB Receptor Network with Trastuzumab and Gefitinib in Patients C07D 239/00 (2006.01) with HER2 (ErbB2)-Overexpressing Metastatic Breast Cancer, Clin C07D 239/02 (2006.01) Cancer Res. Oct. 1, 2008;14(19):6277-83. CO7D 403/00 (2006.01) Bilsky, E.J., et al., Effects of Naloxone and D-Phe-Cys-Tyr-D-Trp CO7D 405/00 (2006.01) Arg-Thr-Phe-Thr-NH2 and the Protein Kinase Inhibitors H7 and H8 CO7D 409/00 (2006.01) on Acute Morphine Dependence and Antinociceptive Tolerance in (52) U.S. Cl. Mice, J. Pharmacol. Exp. Ther. 1996, 277:484-490. USPC ...... 514/252.18; 514/256; 544/242:544/295; Shen, J., et al. An Antibody Directed Against PDGF Receptor b 544/364 Enhances the Antitumor and the Anti-Angiogenic Activities of an Anti-VEGF Receptor 2 Antibody Biochem Biophys Res Commun. (58) Field of Classification Search Jun. 15, 2007: 357(4): 1142-7. Epub Apr. 19, 2007. USPC .................... 514/252.18, 256; 544/242, 295, 544/364 (Continued) See application file for complete search history. Primary Examiner — Kara R McMillian (56) References Cited (74) Attorney, Agent, or Firm — Parker Highlander PLLC U.S. PATENT DOCUMENTS (57) ABSTRACT 6,667,293 B1 12/2003 Zhao et al. Methods of preventing the development and reversing or 6,894,051 B1 5/2005 Zimmermann et al. 7,034,013 B2 4/2006 Thompson et al. partially reversing opioid tolerance in a Subject are provided 7,115,587 B2 10/2006 Nerurkar et al. herein. Such methods include the step of administering to a 7,151,106 B2 12/2006 Hayry subject in need thereofatherapeutically effective amount of a 7,544,799 B2 6/2009 Zimmermann et al. PDGFR modulator or EGFR modulator alone or together 7,629,331 B2 12/2009 Pipkin et al. with an opiate analgesic. The methods can also be used for the 7,635,773 B2 12/2009 Antle 8,049,003 B2 11/2011 Mosher et al. treatment of refractory neuropathic pain, physical depen 2004/O127453 A1* 7/2004 Lyons et al. .................... 514/50 dence or addiction. 2005, 0043233 A1 2/2005 Stefanic et al. 2006/0211752 A1 9, 2006 Kohnet al. 5 Claims, 9 Drawing Sheets US 8,501.740 B2 Page 2 OTHER PUBLICATIONS Ossipov, M.H., et al., The Loss of Antinociceptive Efficacy of Spinal Morphine in Rats With Nerve Ligation Injury Is Prevented by Reduc Chen, L., et al., Protein Kinase C Reduces Mg2+ Block of NMDA ing Spinal Afferent Drive, Neurosci Lett., 1995, 199:87-90. Receptor Channels as a Mechanism of Modulation, Nature, 1992, Paez JG, et. al., EGFR Mutations in Lung Cancer: Correlation With 356:521-523. Clinical Response to Gefitinib Therapy, Science 2004; 304(5676): Chen, L., et al., Sustained Potentiation of NMDA Receptor-Mediated 1497-500. Glutamate Responses Through Activation of Protein Kinase C by a Pasternak, G.W., et al., Mapping of Opioid Receptors. Using u-Opioid, Neuron, 1991, 7:319-326. Antisense Oligodeoxynucleotides: Correlating their Molecular Biol Chung, J.M., H.K. Kim, and K. Chung, Segmental spinal nerve ogy and Pharmacology, 1995, Trends in Pharmacol. Science, 1995, ligation model of neuropathic pain. Methods Mol Med, 2004. 99: p. 16:344-350. 35-45. Druker, B.J., et al., Efficacy and Safety of a Specific Inhibitor of the Sjogren, P. et al., Hyperalgesia and Myoclonus in Terminal Cancer BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia, N. Engl. Patients Treated With Continuous Intravenous Morphine, Pain, 1993, J. Med., 2001, 344:103.1-1037. 55:93-97. Elliott, K., et al., The NMDA Receptor Antagonists, LY274614 and Stewart D, et. al., Gefitinib Maintenance in Stage III Non-Small-Cell MK-801, and the Nitric Oxide Synthase Inhibitor, NG-Nitro-L- Lung Cancer, Clin Oncol. Sep. 8, 2008. Arginine, Attenuate Analgesic Tolerance to the Mu-Opioid Morphine Trang, T., et al., The Role of Spinal Neuropeptides and but not to Kappa Opioids, Pain, 1994.56:69-75. Prostaglandins in Opioid Physical Dependence, Br. J. Pharmacol., Foley, K.M., et al., Opioids and Chronic Neuropathic Pain, NEJM, 2002, 136(1):37-48. 2003, 348: 1279-1281. Wang, H.Y., M. Frankfurt, and L.H. Burns, High-Affinity Naloxone Gutstein and Akil. Opioid Analgesics, Pharmacological Basis of Binding to Filamin A Prevents Mu Opioid Receptor-Gs Coupling Therapeutics, 11th edition 2006, 547-590. Underlying Opioid Tolerance and Dependence, PLoS ONE, 2008. Gutstein and Trujillo, Does Chronic Nociceptive Stimulation Alter Yan L, et. al., Pharmacogenetics and Pharmacogenomics in Oncol the Development of Morphine Tolerance? Brain Research 1995, 680, ogy Therapeutic Antibody Development, BioTechniques 2005; 173-179. 39(4): 565-8. Gutstein et al., MK-801 Inhibits the Development of Morphine Tol Belcheva, MM., et al., The Fibro Growth Factor Is at the Site of erance at Spinal Sites, Brain Research 1993. 626, 332-334. Convergence between u-Opioid Receptor and Growth Factor Signal Gutstein.H.B. The Effects of Pain on Opioid Tolerance: How Do We Resolve the Controversy? Pharmacological Reviews 1996, 48:3. ing Pathways in Rat C6 Glioma Cells, JPET, 2002, 303:3, 909-918. 403-407. Li, J. et al., Mechanism of Agonist-Induced Down-Regulation of the Jordan, B.A., et al., G-protein-Coupled Receptor Heterodimerization Human k-Opioid Receptor: Internalization Is Required for Down Modulates Receptor Function, Nature, 1999, 399:697-700. Regulation, M.Pharm, 2000, 58:4, 795-801. Kieffer, B.L., et al., Opioids: First Lessons from Knockout Mice, Dong et al., "Selective inhibition of PDGFR by imatinib elicits the Trends Pharmacol Sci., 1999, 20: 19-26. Sustained activation of ERK and downstream receptor signaling in Kolesnikov, Y.A., et al., Blockade ofTolerance to Morphinebut not to malignant glioma cells.” International Journal of Oncology, 38:555 Opioids by a Nitric Oxide Synthase Inhibitor, Proc Natl Acad Sci 569, 2011. USA, 1993, 90:5162-516. Chu et al., “BCR/ABL kinase inhibition by imatinib mesylate Kotecha, S.A., et al., A D2 class dopamine receptor transactivates a enhances MAP kinase activity in chronic myelogenous leukemia receptor tyrosine kinase to inhibit NMDA receptor transmission. CD34+ cells.” Blood, 103(8):3167-3174, 2004. Neuron, 2002. 35(6): p. 1111-22. Johnson et al., “Induction of heparin-binding EGF-like growth factor 20. Kumar A. et al., Structure and Clinical Relevance of the Epider and activation of EGF receptor in imatinib mesylate-treated mal Growth Factor Receptor in Human Cancer, JClin Oncol. Apr. 1, squamous carcinoma cells,” Journal of Cellular Physiology, 2008:26(10): 1742-51. 205:218-227, 2005. Lev, D.C., et al., Inhibition of Platelet-Derived Growth Factor Recep Karaman et al., “A quantitative analysis of kinase inhibitor selectiv tor Signaling Restricts the Growth of Human Breast Cancer in the ity.” Nature Biotechnology, 26(1): 127-132, 2008, and Supplemental Bone of Nude Mice, J.